26th May 2021 16:30
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 25 May 2021still |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD | ||||
| Long | Short | ||||
| Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
1,843,844 | 1.43% | 229,695 | 0.18% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
72,359 | 0.06% | 94,581 | 0.07% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 6,100 | 0.00% | 6,100 | 0.00% | |
|
|
|
| ||
| TOTAL: |
|
|
|
| |
1,922,303 | 1.49% | 330,376 | 0.26% | ||
|
|
|
| ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 5 | 262.1640 USD |
Purchase | 9 | 262.5277 USD |
Purchase | 9 | 261.6055 USD |
Purchase | 10 | 262.0600 USD |
Purchase | 29 | 262.5600 USD |
Purchase | 29 | 262.4100 USD |
Purchase | 100 | 261.9700 USD |
Purchase | 100 | 261.5200 USD |
Purchase | 100 | 262.4200 USD |
Purchase | 200 | 262.2975 USD |
Purchase | 200 | 261.7892 USD |
Purchase | 395 | 261.7993 USD |
Purchase | 400 | 262.1850 USD |
Purchase | 533 | 262.5532 USD |
Purchase | 546 | 261.9827 USD |
Purchase | 800 | 262.1062 USD |
Purchase | 835 | 262.1155 USD |
Purchase | 932 | 262.5509 USD |
Purchase | 985 | 262.1764 USD |
Purchase | 1,100 | 262.1927 USD |
Purchase | 1,104 | 262.0595 USD |
Purchase | 1,300 | 262.1023 USD |
Purchase | 1,300 | 261.9775 USD |
Purchase | 1,500 | 262.4009 USD |
Purchase | 1,514 | 262.1349 USD |
Purchase | 1,947 | 262.2724 USD |
Purchase | 2,153 | 262.0877 USD |
Purchase | 3,306 | 262.0669 USD |
Purchase | 4,032 | 262.1631 USD |
Purchase | 4,654 | 262.0478 USD |
Purchase | 4,955 | 262.2331 USD |
Purchase | 12,251 | 262.2035 USD |
Purchase | 18,899 | 261.9499 USD |
Purchase | 31,092 | 261.5900 USD |
Purchase | 62,229 | 262.1167 USD |
Sale | 1 | 262.3300 USD |
Sale | 2 | 262.6100 USD |
Sale | 28 | 262.9400 USD |
Sale | 58 | 262.5600 USD |
Sale | 100 | 261.9650 USD |
Sale | 271 | 262.1478 USD |
Sale | 300 | 262.6375 USD |
Sale | 384 | 262.0509 USD |
Sale | 600 | 262.4875 USD |
Sale | 800 | 262.5275 USD |
Sale | 1,075 | 262.4830 USD |
Sale | 1,341 | 262.5374 USD |
Sale | 1,500 | 262.0792 USD |
Sale | 1,500 | 262.4009 USD |
Sale | 1,585 | 262.5286 USD |
Sale | 1,800 | 262.4772 USD |
Sale | 1,982 | 262.5712 USD |
Sale | 2,077 | 262.1502 USD |
Sale | 2,578 | 262.2529 USD |
Sale | 2,651 | 262.0609 USD |
Sale | 3,655 | 262.1493 USD |
Sale | 9,941 | 262.5684 USD |
Sale | 11,532 | 262.1002 USD |
Sale | 13,771 | 262.1925 USD |
Sale | 20,873 | 261.9700 USD |
Sale | 30,528 | 262.1644 USD |
Sale | 30,778 | 261.5900 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | YES |
| Date of disclosure: | 26 May 2021 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
| Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price | date | ||
| to which the option | |||||
| or derivative | |||||
| relates | |||||
Put Options | Purchased | -100 | 220.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 100 | 240.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005852/en/
Copyright Business Wire 2021
Related Shares:
Barclays